Nature Communications (Sep 2017)
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
- Rina M. Mbofung,
- Jodi A. McKenzie,
- Shruti Malu,
- Min Zhang,
- Weiyi Peng,
- Chengwen Liu,
- Isere Kuiatse,
- Trang Tieu,
- Leila Williams,
- Seram Devi,
- Emily Ashkin,
- Chunyu Xu,
- Lu Huang,
- Minying Zhang,
- Amjad H. Talukder,
- Satyendra C. Tripathi,
- Hiep Khong,
- Nikunj Satani,
- Florian L. Muller,
- Jason Roszik,
- Timothy Heffernan,
- James P. Allison,
- Gregory Lizee,
- Sam M. Hanash,
- David Proia,
- Rodabe Amaria,
- R. Eric Davis,
- Patrick Hwu
Affiliations
- Rina M. Mbofung
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Jodi A. McKenzie
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Shruti Malu
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Min Zhang
- Department of Lymphoma/Myeloma Unit 903, The University of Texas MD Anderson Cancer Center
- Weiyi Peng
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Chengwen Liu
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Isere Kuiatse
- Department of Lymphoma/Myeloma Unit 903, The University of Texas MD Anderson Cancer Center
- Trang Tieu
- Institute for Applied Cancer Sciences Unit 1956, The University of Texas MD Anderson Cancer Center
- Leila Williams
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Seram Devi
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Emily Ashkin
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Chunyu Xu
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Lu Huang
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Minying Zhang
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Amjad H. Talukder
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Satyendra C. Tripathi
- Department of Clinical Cancer Prevention Unit 1013, The University of Texas MD Anderson Cancer Center
- Hiep Khong
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Nikunj Satani
- Cancer Imaging Systems Unit 1907, The University of Texas MD Anderson Cancer Center
- Florian L. Muller
- Cancer Imaging Systems Unit 1907, The University of Texas MD Anderson Cancer Center
- Jason Roszik
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Timothy Heffernan
- Institute for Applied Cancer Sciences Unit 1956, The University of Texas MD Anderson Cancer Center
- James P. Allison
- Department of Immunology Unit 901, The University of Texas MD Anderson Cancer Center
- Gregory Lizee
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- Sam M. Hanash
- Department of Clinical Cancer Prevention Unit 1013, The University of Texas MD Anderson Cancer Center
- David Proia
- Synta Pharmaceuticals Inc.
- Rodabe Amaria
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- R. Eric Davis
- Department of Lymphoma/Myeloma Unit 903, The University of Texas MD Anderson Cancer Center
- Patrick Hwu
- Department of Melanoma Medical Oncology Unit 904, The University of Texas MD Anderson Cancer Center
- DOI
- https://doi.org/10.1038/s41467-017-00449-z
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 8
Abstract
Many patients fail to respond to T cell based immunotherapies. Here, the authors, through a high-throughput screening, identify HSP90 inhibitors as a class of preferred drugs for treatment combination with immunotherapy.
